6826 — Shanghai Haohai Biological Technology Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapSuper Stock

Market Cap
HK$6.31bn
Enterprise Value
HK$4.16bn
Revenue
CNY2.65bn

Annual income statement for Shanghai Haohai Biological Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,604	1,332	1,767	2,130	2,654
Cost of Revenue
Gross Profit	1,240	994	1,275	1,461	1,864
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,169	1,074	1,384	1,896	2,147
Operating Profit	435	259	383	234	507
Gain / Loss on Sale of Assets
Other Net Non Operating Costs
Net Income Before Taxes	434	257	383	236	508
Provision for Income Taxes
Net Income After Taxes	376	226	347	190	412
Minority Interest
Net Income Before Extraordinary Items
Net Income	371	230	352	180	416
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	371	230	352	180	416
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.32	1.31	2.01	1.26	2.44
Dividends per Share